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OBJECTIVES: Nationwide organized breast cancer program
was introduced in 2002 in Hungary. The purpose of this study
is to analyze the effect of breast cancer screening program on the
number and ration of breast surgeries. METHODS: The data
derived from the ﬁnancial database of the National Health Insur-
ance Fund Administration. We identiﬁed the patients with ICD
codes and Diagnosis Related Groups (DRG). The study covers
the ﬁve-year period between 2000–2004. We deﬁned total mas-
tectomy as the removal of preferably all breast tissue. Subtotal
mastectomy (e.g. quadrantectomy) is deﬁned as breast conserv-
ing surgery. We carried out the detailed analysis for the years
2000–2001, without nationwide organized screening program,
and for the years 2002–2003 (ﬁrst screening round) after the
implementation of nationwide organized breast cancer screening
program. RESULTS: The total number of breast surgeries was
7306 in 2000 and 7549 in 2001. After the introduction of the
nation wide organized breast cancer screening program the total
number of breast surgeries increased to 8531 in 2002 and 9140
in 2003. Compared to the values of 2000 as 100%, the number
of total mastectomies increased 107.8% in 2002 and 109.6%,
while the number of subtotal mastectomies increased much
more: 120.3% in 2002 and 127.4% in 2003. The ratio of total
and subtotal mastectomies in 2000 was 46.2% versus 53.8%.
By 2004 the proportion of total mastectomies decreased to 
40.0% and the proportion of subtotal mastectomies increased to
60%. The number of surgeries because of benign cases has also
increased. CONCLUSIONS: The introduction of organized
nationwide breast cancer screening program increased the total
number of breast surgeries. Within the total number of breast
surgeries decreased the proportion of total and increased the pro-
portion of subtotal or breast conserving mastectomies.
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OBJECTIVE: The risk cut off to recommend BRCA 1 and 2 gene
testing varies from 10% for the American Society of Clinical
Oncology to 20% in European countries. Considering pts with
a previous diagnosis of breast cancer, we aimed to establish a
risk cut off policy for genetic testing at our service, in terms of
direct costs. A total of 130pts with a previous breast cancer, in
routine follow-up, received invitation to schedule consultation in
the hereditary breast cancer unit. METHODS: Of these, 77
patients, were interviewed by a multidisciplinary team, and had
their risk assessed based on family pedigree and conﬁrmed
pathological information (Frank Ts et al, JCO 20:1480–1490,
2002). Direct costs of genetic testing were considered as the sum
of costs of reagents, permanent equipment and personnel
excluded. Prices in reais were converted to dolar (2.3 reais per
dolar). RESULTS: Our survey have shown that 3 women in 77
surveyed were to be tested with a risk cut off established in 20%
as compared to 16 with a risk assessment of >10%. Consider-
ing the offspring, screening those women would beneﬁt 162 and
21other women, respectively, at 10% and 20% cut off. The total
direct costs of gene testing would be $31,023.86 at 10% and
$5816.97 at 20%. In case we consider all ﬁrst degree women rel-
atives as beneﬁciaries, independent of the result being positive or
negative for BRCA mutation, cost effectiveness (CE) ratio of
$191.50 per individual beneﬁted at 10% and $276.99/beneﬁ-
ciary at 20%. CONCLUSION: A 20% cut off for genetic testing
in this population with breast cancer seems very strict, since the
number of women indicated for genetic testing was far bellow
the 5% expected in breast cancer population. Considering the
other family members, the higher cost associated with 10% cut
off could beneﬁt more women.
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REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A
NATIONWIDE SAMPLE OF PATIENTS WITH CANCER
RECEIVING CHEMOTHERAPY: RESULTS FROM A LARGE
RETROSPECTIVE OBSERVATIONAL STUDY
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OBJECTIVES: To better understand the real-world dosing pat-
terns of epoetin alfa (EPO) and darbepoetin alfa (DARB) in
patients with cancer receiving chemotherapy, a large retrospec-
tive, observational study was undertaken to analyze dosing pat-
terns and associated costs of patients treated with EPO and
DARB in the outpatient setting. METHODS: Adult patients who
had cancer and were receiving chemotherapy, had ≥2 EPO or
DARB claims, and were newly initiated on erythropoiesis stim-
ulating therapy (EST) between April 2003 and February 2005
were identiﬁed from a nationwide sample of outpatient medical
claims from hospital clinics and ofﬁce practices. EPO and DARB
use was identiﬁed via HCPCS codes in medical claims with dose
calculated using billed units. Average treatment duration, dosing
frequency, mean cumulative dose, and total EST costs (using
2005 wholesale acquisition prices) were studied. RESULTS: A
total of 1405 EPO and 1087 DARB patients met the inclusion
criteria. Mean age (years; EPO 63 ± 13; DARB 62 ± 12) was
similar between groups, with more women in the DARB group
(EPO 62%; DARB 71%, p < 0.05). Weekly and extended dosing
(≥Q2W) frequencies were utilized in patients receiving EPO
(QW: 65%, Q2W: 29%, ≥Q3W: 6%) and DARB (QW: 11%,
Q2W: 61%, ≥Q3W: 28%). Mean treatment duration was 54 ±
51 days for EPO and 52 ± 46 days for DARB. Mean cumulative
dose for EPO and DARB was 296,070 IU and 1022mcg corre-
sponding to a dose only ratio of 290 :1 (units EPO: mcg DARB)
and total EST costs of $3603 and $4456, respectively. CON-
CLUSION: In this large observational study, DARB treatment
costs were substantially higher (24%) than EPO treatment costs.
In addition, extended EPO and DARB dosing was common
among patients with cancer receiving chemotherapy.
CANCER—Methods and Concepts
PCN26
INTER-RATER AGREEMENT OF HUI3 UTILITY SCORES FOR
PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE
LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT
VERSUS CLINICIAN ASSESSMENT
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OBJECTIVES: To assess inter-rater agreement for Health Utili-
ties Index (HUI) Mark 3 (HUI3) measurements of patients
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during treatment of acute lymphoblastic leukemia (ALL) in
childhood. METHODS: Patients were age ﬁve years or older at
time of study and enrolled in Dana Farber Cancer Institute 95-
001 clinical trial. Parents-of-patients and clinicians, blinded to
each other, completed self-administered HUI questionnaires at
four assessment points during treatment: Induction of remission,
CNS prophylaxis, intensiﬁcation, and maintenance. Agreement
between parents and clinicians, for HUI3 single-attribute and
overall health-related quality of life (HRQL) utility scores, was
assessed using a single-measure two-way mixed model intra-class
correlation coefﬁcient (ICC) and paired t-test. Mean differences
in single-attribute and HRQL scores >0.05 and >0.03, respec-
tively, are clinically important. Statistical signiﬁcance was set at
p < 0.05. ICC results were interpreted as follows: >0.50 strong
agreement; 0.35–0.50 moderate agreement; 0.20–0.34 weak
agreement; 0.00–0.19 negligible agreement. RESULTS: There
were 375 patients who were surveyed (55.2% males). The
number of pairs of parent and clinician assessments varied by
assessment point (minimum = 104, maximum = 180). There was
moderate or better agreement between raters (p < 0.05) at all
assessment points for ambulation (ICC = 0.51–0.84) and pain
(ICC = 0.39–0.84). Weak or better agreement (p < 0.05) was
observed at all assessment points for vision (ICC = 0.23–0.79),
and emotion (ICC = 0.22–0.69). Inter-rater agreement for HRQL
ranged from weak to moderate (ICC = 0.31–0.50, p < 0.05).
There was no signiﬁcant agreement (p > 0.05) for dexterity at
any assessment point (ICC = 0.05–0.16) and for cognition at
Induction (ICC < 0.01). The mean difference (clinician minus
parent) was clinically important for HRQL (difference = 0.07, p
= 0.01) at Maintenance. CONCLUSIONS: Inter-rater agreement
varies, from none to strong, by both type of utility score and
assessment point. A clinically important mean difference in
HRQL scores was observed. Parent and clinician reports should
not be considered interchangeable. The results are consistent
with studies of ALL patients assessed after completion of
therapy.
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OBJECTIVES: The ﬁve-year mortality rate for a population of
adult brain tumor patients is typically high (≥50%). Tumor grade
is a well-known predictor for mortality: low-grade (LG) tumors
are associated with lower mortality rates than are high-grade
(HG) tumors. METHODS: Prospective study of consecutive
patients newly diagnosed with primary brain tumors attending
a single regional centre. A cross-sectional survey collected base-
line health status assessments for each patient after diagnosis,
and in most cases surgery, but before radiotherapy or chemother-
apy. Each participating patient completed a Health Utilities
Index (HUI) Mark 2 (HUI2) and Mark 3 (HUI3) 15-item self-
complete questionnaire, prior to encounter with assessing physi-
cian. The assessing physician, blind to patient’s assessment,
recorded a Karnofsky Performance Score (KPS) and a Mini-
Mental Status Examination (MMSE) score. The life status for
each patient was determined for the ﬁve-year period after assess-
ment. Proportional hazards models estimated the IHOD for dif-
ferences of: 0.10 in HUI utility scores; ten units in KPS; and ﬁve
units in MMSE. Statistical signiﬁcance was set at the 5% level.
RESULTS: HUI2 self-care was the only health status measure
associated with a signiﬁcant IHOD for LG tumors (n = 25): a
decrease of 0.10 in HUI2 self-care score being associated with a
30% IHOD (p = 0.023). Among patients with HG tumors (n =
56), 3 measures were independently signiﬁcant: KPS (20%
IHOD, p = 0.022); MMSE (26% IHOD, p = 0.015) and HUI3
dexterity (18% IHOD, p = 0.035). Two measures, together, were
signiﬁcant among HG patients: MMSE (29% IHOD, p = 0.007)
and HUI3 dexterity (20% IHOD, p = 0.020). CONCLUSION:
Only HUI measures were signiﬁcant predictors of IHOD for both
LG and HG patients. MMSE and HUI3 dexterity, in combina-
tion, were signiﬁcant predictors for HG patients. The latter is
evidence that patient- and physician-reported measures provide
important complementary types of information.
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OBJECTIVES: To assess economic appraisals of chemotherapy
regimens for metastatic colorectal cancer (mCRC) published in
peer-reviewed journals. METHODS: A PubMed search of
English-language documents published up to October 2004 was
conducted using the search terms: “chemotherapy”, “metasta-
tic”, “colorectal cancer”, and “economic”, “cost-effectiveness”,
or “cost-beneﬁt”. Additional publications were identiﬁed from
references, reviews, and meta-analyses. Publications were
reviewed for information on the type of cost analyses, year of
publication, journal, country, perspective, type of chemotherapy
assessed, data collection methods, sponsorship, and types of sen-
sitivity analyses conducted. RESULTS: Economic analyses were
published on eight regimens. Seven of the 14 published studies
were published from a UK perspective, and 2 each from a French
and a Dutch perspective; no study has been published from the
US perspective. Ten studies were cost-consequences and four
were cost-effectiveness analyses. Limited documentation was
provided on sources of costs for medical resource use. Adjust-
ments for quality of life were considered in sensitivity analyses
in two studies designed to inform guidance by the UK’s National
Institute of Clinical Excellence. Overall, drug costs accounted for
1%–37% of total expenditures for 5-ﬂourauracil + leucovorin
(5FU/LV) regimens, in contrast to 47%–83% of total expendi-
tures for newer combination regimens (e.g., irinotecan + 5FU/LV,
oxaliplatin +5FU/LV, capecitabine). No formal analyses were
published on Avastin (bevacizumab) or Erbitux (cetuximab).
Discounting for future costs and beneﬁts was not done in any
analysis. CONCLUSIONS: Some prominent novel regimens for
mCRC have no publicly available economic appraisal. Among
the few published studies on older regimens, most omit compo-
nents such as quality-of-life adjustments, discounting, and 
transparent statements on data sources for prices that are rec-
ommended in ISPOR’s statement on “Good Research Practices—
Modeling Studies.”
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OBJECTIVE: This study seeks to synthesize and identify gaps in
the economic literature of prostate cancer (PCA). METHODS:
English-language abstracts and articles published between 1990
